Guggenheim Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $558
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Debjit Chattopadhyay maintains a Buy rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raises the price target from $450 to $558.
August 02, 2024 | 7:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst Debjit Chattopadhyay maintains a Buy rating on Vertex Pharmaceuticals and raises the price target from $450 to $558.
The Buy rating and increased price target from a reputable analyst at Guggenheim is likely to positively influence investor sentiment and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100